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Clinical trialson's disease signiﬁcantly improve the quality of life for patients suffering from
this neurodegenerative disease, yet none of the current therapies has been convincingly shown to slow or
prevent the progression of disease. Much has been learned about the pathophysiology of Parkinson's disease
in recent years, and these discoveries offer a variety of potential targets for protective therapy. Mechanisms
implicated in the disease process include oxidative stress, mitochondrial dysfunction, protein aggregation
and misfolding, inﬂammation, excitotoxicity, and apoptosis. At the same time, the involvement of these
diverse processes makes modeling the disease and evaluation of potential treatments difﬁcult. In addition,
available clinical tools are limited in their ability to monitor the progression of the disease. In this review, we
summarize the different pathogenic mechanisms implicated in Parkinson's disease and neuroprotective
strategies targeting these mechanisms currently under clinical study or under preclinical development, with
a view towards strategies that seem most promising.
© 2008 Elsevier B.V. All rights reserved.Parkinson's disease (PD) is a progressive neurodegenerative disease
causing tremor, rigidity, bradykinesia, and gait impairment. Thesemotor
deﬁcits have been mainly attributed to the progressive loss of
dopaminergic neurons in the substantia nigra (SN), and consequently
the focus of current PD therapy has been on the replacement of
dopamine. This approach has, in some respects, been remarkably
effective andhas led to treatmentswhich can substantially improveboth
the duration and quality of life of patients affected by PD. Ultimately,
however, most patients developmotor complicationswhich are difﬁcult
to control with currently available treatments. In addition, they develop
a variety of non-motor symptoms, including anosmia, sleep disorders,
autonomic impairment, and cognitive impairment. These non-motor
symptoms are refractory to most current treatments, and frequently
become themost signiﬁcant source of disability. The complexity of these
late-stage complications points to the importance of developing
neuroprotective strategies which could be applied early in the disease
in order to prevent or delay the later complications of the disorder.
Pathological studies have shown that dopaminergic degeneration
is only a small part of a much broader spectrum of PD-related
neurodegeneration that may begin with pathology in the brainstem
and then progress beyond the SN to cortical and subcortical regions
[1]. In this current view, the overall duration of PD spans decades from
the ﬁrst signs to the late stages, with involvement of themotor system
only in the middle stages. The long, slow course of neurologic
impairment in PD offers an important opportunity: if treatments that
delay or prevent the neurodegenerative process are developed, they6, Birmingham, AL 35294, USA.
).
ll rights reserved.could be employed at an early stage of the disease to prevent the
severely debilitating complications of advanced PD. Indeed, it is likely
that technologies that can detect the disease process before the onset
of visible symptoms will become practical in the near future; the main
barrier to progress against PD is the lack of a meaningful neuropro-
tective treatment that can be applied after the disease is identiﬁed.
In this review, we deﬁne “neuroprotective” therapies as those that
slow or prevent further neurodegeneration of neuronal populations
involved in PD, both dopaminergic and non-dopaminergic. Our
deﬁnition for “neuroprotection” does not include “neurorestorative”
strategies that aim to replace neuronal elements after they are lost (for
example, fetal tissue or stem-cell-based transplants). Currently, there
are no treatments that are clearly established as neuroprotective in
PD, and the discovery of such treatments is an important goal of much
work in the ﬁeld.
1. Mechanisms for PD pathogenesis and targets
for neuroprotection
An understanding of the mechanisms underlying the development
and progression of PD pathology is critical for the development of
neuroprotective therapies. A complex interplay of multiple environ-
mental and genetic factors has been implicated in PD, suggesting that
PD likely represents a syndrome instead of a single disorder with the
same primary cause in all cases. Several mechanisms have been
implicated as crucial to PD pathogenesis: oxidative stress, mitochon-
drial dysfunction, protein aggregation and misfolding, inﬂammation,
excitotoxicity, apoptosis and other cell death pathways, and loss of
trophic support (Table 1). No onemechanism appears to be primary in
all cases of PD, and these pathogenic mechanisms likely act
Table 1
Mechanisms of PD pathogenesis and targets for therapy
PD pathogenic
mechanism
Targets for neuroprotection
Oxidative stress and
mitochondrial
dysfunction
Inhibitors of dopamine metabolism (e.g. MAO inhibitors,
dopamine receptor agonists)
Electron transport enhancers (e.g. CoQ10)
Other antioxidants (e.g. vitamin E, uric acid)
Glutathione promoters (e.g. selenium)
Protein aggregation
and misfolding
Inhibitors of α-syn aggregation
Agents that reduce α-syn protein levels
Enhancers of parkin function
Enhancers of UCH-L1 function
Enhancers of proteosomal or lysosomal pathways
Neuroinﬂammation Anti-inﬂammatory agents (e.g. NSAIDs, statins, minocycline)
Excitotoxicity NMDA receptor antagonists
Calcium channel antagonists
Apoptosis and cell
death pathways
Anti-apoptotic agents
Loss of trophic factors Neurotrophic factors (e.g. GDNF, neurturin)
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generation. Discussion of these mechanisms is brieﬂy reviewed here
in reference to their implications for the development of neuropro-
tective therapies. The reader is referred to other reviews in this issue
that address PD pathogenesis in more detail.
1.1. Oxidative stress and mitochondrial dysfunction
Oxidative stress results from an overabundance of reactive free
radicals secondary to either an overproduction of reactive species or a
failure of cell buffering mechanisms that normally limit their
accumulation. Excess reactive species can react with cellular macro-
molecules and thereby disrupt their normal functions. Oxidative
damage to proteins, lipids, and nucleic acids has been found in the SN
of patients with PD [2–4]. Both overproduction of reactive species and
failure of cellular protective mechanisms appear to be operative in PD.
Dopamine metabolism promotes oxidative stress through the
production of quinones, peroxides, and other reactive oxygen species
(ROS) [5,6]. Mitochondrial dysfunction is another source for the
production of ROS, which can then further damage mitochondria.
Complex I activity is diminished in the SN of PD patients [7], while
inhibitors of complex I, such as MPP+ and rotenone, cause a
Parkinsonian syndrome in animal models [8–10]. The mechanisms
responsible for mitochondrial dysfunction in PD are not well under-
stood, but inherited or acquired mutations in mitochondrial DNA may
contribute [11–13]. Increased iron levels seen in the SN of PD patients
[14,15] also promote free radical damage, particularly in the presence of
neuromelanin.
There is also evidence of impairment of endogenous protective
mechanisms in PD. The antioxidant protein glutathione is reduced in
postmortem PD nigra [16–18]. Several of the genes linked to familial
formsof PDappear to be involved inprotection against oxidative stress,
including PTEN-induced putative kinase (PINK1) and DJ-1 [19–22].
Several different strategies have been proposed to limit oxidative
stress in PD. These strategies include inhibitors ofmonoamine oxidase, a
key enzyme involved in dopamine catabolism; enhancers of mitochon-
drial electron transport, such as Coenzyme Q10; compounds that can
directly quench free radicals, such as vitamin E; and molecules that can
promote endogenous mechanisms to buffer free radicals, such as
selenium. The advantage of many of these agents is that they are well
toleratedwith fewadverse effects, although convincing clinical evidence
for the effectiveness of this approach is still lacking.1.2. Protein aggregation and misfolding
Protein aggregation and misfolding have emerged as important
mechanisms in many neurodegenerative disorders, including PD,
Alzheimer's disease, and Huntington's disease. While the proteins
involved in these disorders are different, each is associated with
characteristic aggregates of misfolded protein, and these abnormal
aggregates appear to acquire toxic properties.
In PD, the primary aggregating protein is alpha-synuclein (α-syn),
whose link to PD was ﬁrst identiﬁed through rare families with
autosomal dominant PD caused by mutations in this protein [23–26].
While mutations in α-syn are found in a very small number of
inherited PD cases, α-syn is the major component of Lewy bodies and
Lewy neurites found in sporadic PD [27,28]. Gene duplication of theα-
syn locus also causes PD, further supporting the central role of this
protein in PD pathogenesis [29]. Point mutations [30–33], over-
expression [34], and oxidative damage of α-syn [35] have all been
postulated to promote self-aggregation.
While abundant evidence links α-syn to PD, the mechanism by
which overabundance or aggregation of α-syn causes neuronal injury
is not understood. Likewise, it is unclear which molecular form of α-
syn is toxic. Hypotheses include toxic effects of oligomers on cell
membranes or proteosomal function, effects of α-syn on gene
transcription or regulation, interactions of α-syn with cell signaling
and cell death cascades, alterations in dopamine storage and release,
andα-syn-mediated activation of inﬂammatory mechanisms [36–46].
Recent studies implicating parkin and ubiquitin carboxyl-terminal
hydrolase L1 (UCH-L1) in genetic forms of PD reinforce the connection
between protein aggregation and PD pathogenesis [47,48]. Parkin is an
E3 ubiquitin ligase involved in targeting misfolded proteins for
degradation, and mutations of parkin found in genetic forms of PD
disrupt its E3 ubiquitin ligase activity [49–51]. Interestingly, native α-
syn does not appear to be a substrate for parkin, although modiﬁed
formsmay be [52,53], and brains frompatients with parkin-associated
PD do not usually contain Lewy bodies [54–57]. Parkin does appear to
have a variety of other substrates that may play a role in protein
turnover and degradation, including HSP70, which is known to
modulate α-syn toxicity [58,59]. UCH-L1 serves as an ubiquitin
recycling enzyme in neurons, and its dysfunction promotes aggrega-
tion of damaged proteins, including α-syn [60–62].
Together, these observations suggest that overproduction or
impaired clearance of α-syn, resulting in aggregation, may be a
central mechanism for PD. Therefore, therapeutic strategies to prevent
protein aggregation or to enhance the clearance of misfolded proteins
are the subject of intensive study at present. Inhibitors of α-syn
aggregation could serve as potential neuroprotective therapies,
although a clearer understanding of the toxic form of α-syn is
important. Molecules that promote protein clearance could also have
therapeutic potential. Promoters of protein clearance could include
enhancers of parkin or UCH-L1 function, or molecules that promote
proteosomal or lysosomal degradation pathways.
1.3. Neuroinﬂammation
Neuroinﬂammation has been increasingly recognized as a primary
mechanism involved in PD pathogenesis [63–65]. Activation of
microglia has been demonstrated in SNand striatum frompostmortem
PD brains and in PD animal models [66–70]. Pro-inﬂammatory
cytokines, such as IL-1β, IL-6, and TNF-α, are elevated in the CSF and
basal ganglia in PD patients [71,72]. The complement system is also
implicated in PD pathogenesis, as elevated serum levels of comple-
ment proteins and the presence of complement proteins in Lewy
bodies have been detected in PD [73,74]. How microglia become
activated in PD is not fully understood, but both cytokines and α-syn
aggregation can promote microglia activation [65]. In vitro, both
aggregated andnitrated forms ofα-syn can directly trigger amicroglial
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syn or modiﬁed forms of the protein can trigger both microglial and
humoral responses [45,46], and inhibition of NF-KB signaling is
neuroprotective [78].
Given the evidence for neuroinﬂammation in PD, agents with anti-
inﬂammatory effects have been investigated for their neuroprotective
potential. Many of these anti-inﬂammatory drugs are already in
common use for other indications. Non-steroidal anti-inﬂammatory
agents (NSAIDs) reduce dopaminergic cell death in animal and culture
PD models (reviewed in [64]), and epidemiological studies have
suggested that certain NSAIDs and statin drugs may reduce PD risk
[79–85]. Minocycline is another agent with anti-inﬂammatory
capabilities that is currently being investigated in human trials [86].
1.4. Excitotoxicity
Excitotoxicity has been implicated as a pathogenic mechanism in
several neurodegenerative disorders, including PD. Glutamate is the
primary excitatory transmitter in the mammalian central nervous
system and a primary driver of the excitotoxic process. Dopaminergic
neurons in the SN have high levels of glutamate receptors and receive
glutamatergic innervation from the subthalamic nucleus and cortex.
Excessive NMDA receptor activation by glutamate could increase
intracellular calcium levels that then activate cell death pathways [87].
Calcium inﬂux produced by excessive glutamate receptor activation
can also promote peroxynitrite production through the activation of
nitric oxide synthase [88]. Levels of 3-nitrotyrosine, a marker of
peroxynitrite formation, are increased in postmortem SN from PD
patients [89]. NMDA receptor antagonists protect against dopaminer-
gic cell loss in MPTP models [90,91], but a major limitation to clinical
application is the low potency and poor tolerability of currently
available agents. Riluzole has glutamate antagonist properties, but a
small clinical trial failed to show any neuroprotective effect [92].
Neuroprotective effects have also been attributed to amantadine,
which has modest NMDA antagonist properties as well as other
actions [93]. Human dopaminergic neurons have NMDA receptors
with an unusual subunit composition characterized by abundant
expression of the NR2D subunits, which have physiological and
pharmacological properties distinct from the receptor types found in
many other regions of the brain [94]. The most promising opportunity
for the use of glutamate antagonists as neuroprotective agents for PD
may lie in the development of NMDA antagonists with selectivity for
speciﬁc channel subunits [95].
Another approach to modifying excitotoxicity is to address the
downstream processes, which include intracellular calcium and
related signaling systems. An important recent development is the
discovery of the calcium-dependent pacemaking properties of nigral
dopaminergic neurons, which expose the cells to high levels of
intracellular calcium in the course of normal physiological activity
(reviewed in [96]). This reliance on calcium channels results in a large
energetic burden for these neurons, as intracellular calcium has to be
sequestered regularly into the endoplasmic reticulum and mitochon-
dria to prevent the activation of cell death pathways. The consequence
is nigral cell aging through the production of free radicals and ROS.
Blockade of L-type Cav1.3 calcium channels leads to a reversion of the
cells to a “juvenile” Na+-dependent form of pacemaking and
resistance to MPTP and 6-OHDA toxicity in mice [97]. Epidemiological
studies have suggested that patients treatedwith dihydropyridines for
hypertension have a lower incidence of PD [98]. The dihydropyridine
isradipine is currently being investigated as a potential neuroprotec-
tive agent.
1.5. Apoptosis
Apoptosis, or programmed cell death, is a mechanism that has
been demonstrated to participate in neural development and to play arole in some forms of neural injury. There has been controversy as to
whether apoptosis is directly involved in PD. Several pathological
studies have revealed signs of both apoptotic and autophagic cell
death in the SN of PD brains [99–103], although the extent is limited,
perhaps because of the slow process of cell death which underlies PD.
Apoptotic cell death has also been observed in animal PD models
(reviewed in [104–106]). Alterations in cell death pathways are
unlikely to be the primary cause for PD, but both apoptotic and
autophagic cell death pathways are hypothesized to become activated
in PD through oxidative stress, protein aggregation, excitotoxicity, or
inﬂammatory processes. Activation of these cell death pathways most
likely represents end-stage processes in PD neurodegeneration.
Therefore, inhibitors of these cell death pathways have been proposed
as potential neuroprotective agents regardless of the initial cause for
neurodegeneration in PD. Two different compounds that inhibit
apoptotic signaling have been recently tested in human PD trials (see
below; [107,108]).
1.6. Loss of trophic factors
The loss of neurotrophic factors has been implicated as a potential
contributor to cell death observed in PD. The neurotrophic factors
brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic
factor (GDNF), and nerve growth factor (NGF) have all been
demonstrated to be reduced in the nigra in PD [109–111]. As a result,
treatment with growth factors has been proposed as a potential
neuroprotective therapy in PD. Indeed, the potent ability of these
agents to stimulate growth and arborization of dopaminergic neurons
suggests that they may be useful neuroprotective treatments, even if
deﬁciency of the factors is not the primary cause of the disease
process. GDNF and a related growth factor, neurturin, are both
protective against neurodegeneration in animal models [112–116].
GDNF has been evaluated in human trials [117–120], and neurturin is
currently being investigated in a phase II trial (see below).
2. Current state of neuroprotection in clinical studies
While many drugs have shown promise in animal PD models, this
promise has not yet translated into therapies that are clearly neuropro-
tective in human PD. A recent practice parameter from the American
Academy of Neurology concluded that “no treatment has been shown to
be neuroprotective” [121]. The barriers to establishing a neuroprotective
therapy stem from the complexity of the disease process as well as the
limits of the clinical tools available to monitor the progression of the
disease and to observe the effects of an intervention. Recent studies
seeking a neuroprotective effect illustrate the importance of both of
these factors. Readers are referred to the recent review on neuroprotec-
tion clinical trials for a more comprehensive list of trials [122].
2.1. Levo-dopa as a neuroprotective agent: the ELLDOPA trial
Levodopa (L-dopa) is one of the oldest andmost effective therapies
for the symptoms of PD. Although widely used, until recently there
was little data on the impact of L-dopa therapy on the long-term
progression of PD. Because dopamine catabolism produces free
radicals, there has been concern that treatment of PD patients with
the precursor L-dopa could potentially promote neurodegeneration in
PD [123,124]. On the other hand, a variety of preclinical data has
suggested a neuroprotective effect [125,126].
The Earlier versus Later L-dopa (ELLDOPA) trial was a placebo-
controlled, double-blind study designed to evaluate whether treat-
ment of PD patients with L-dopa modiﬁed disease progression as
compared to those treated with placebo [127]. 361 patients were
treated with placebo or L-dopa at 150 mg/day, 300 mg/day, or
600 mg/day for 40 weeks, followed by a two week washout period.
The primary outcome measure was change in UPDRS score from
Fig. 1. Schematic description of the delayed-start design. Patients are randomized to
either immediate or delayed initiation of the therapeutic agent. Patients in the
immediate group start active therapy at the onset of the study and stay on active
therapy for the duration of the trial. Those randomized to delayed initiation take placebo
initially for a predetermined time period and then are switched to active therapy.
679T.A. Yacoubian, D.G. Standaert / Biochimica et Biophysica Acta 1792 (2009) 676–687baseline. Patients on L-dopa, particularly those on the highest dose,
showed a smaller change in UPDRS score from baseline than those on
placebo. This result suggests that L-dopa does not have a deleterious
effect, but instead is neuroprotective. This interpretation has been
controversial, as the ﬁnding could be explained by the possibility that
the effects of L-dopa outlasted the two-week washout period. In
addition, a secondary outcome measure of the trial, β-CIT neuroima-
ging, suggested the opposite conclusion, with patients on the highest
dose of L-dopa showing the greatest decline in the uptake of β-CIT, a
dopamine transporter ligand.
The ELLDOPA trial illustrates some of the most confounding issues
in studies of PD neuroprotection. The potent effect of many
dopaminergic agents on the symptoms of the disease can make
assessment of the rate of progression difﬁcult. Neuroimaging
techniques are a more direct measure of the physiology of brain
dopamine systems, but the reliability of these techniques as measures
for PD progression remains uncertain [128,129]. At this time, it is not
clear whether L-dopa is neuroprotective, but fears of its potential
toxicity have been somewhat allayed by the ELLDOPA trial.
2.2. Dopamine receptor agonists
Dopamine receptor agonists have been hypothesized as potentially
neuroprotective by acting at D2 autoreceptors found on dopaminergic
SN terminals to suppress dopamine release and thus reduce oxidative
stress. Indeed, in vitro and animal studies have shown that dopamine
receptor agonists can reduce dopaminergic cell death [130–137].
Certain agonists, such as pramipexole, may also act as direct
antioxidants because of their hydroxylated benzyl ring structure
[130,138].
Two large-scale clinical trials have attempted to assess the
neuroprotective properties of dopamine agonist drugs using
neuroimaging strategies. The CALM-PD trial compared pramipexole
to L-dopa treatment in patients with early PD [139]. In this study all
the patients received an active treatment: 301 patients were
randomized to pramipexole or L-dopa. In a subset of 82 patients,
the uptake of radiolabeled β-CIT was assessed. Patients treated with
pramipexole did show less of a decline in β-CIT uptake compared to
those treated with L-dopa alone. A similar result was obtained in the
REAL-PET trial, which compared patients with early PD treated with
ropinirole to those treated with L-dopa [140]. 162 patients had
ﬂuorodopa (18F-dopa) PET imaging to assess 18F-dopa uptake in the
putamen at 4weeks and at 24months after initiating drug treatment.
Patients on ropinirole showed less of a decrease in putaminal 18F-
dopa uptake. While both of these studies suggest a neuroprotective
effect of dopamine agonists, there are several important limitations,
including lack of a placebo control and lack of an extendedwashout of
the medications. In addition, clinical outcome measures revealed
either no difference or even less of an improvement in UPDRS in
patients treated with the dopamine agonist as compared to L-dopa.
The most substantial limitation of these studies is the difﬁculty of
establishing that the neuroimaging measures reﬂect long-term
neuroprotection of dopamine systems, and not short-term pharma-
cological modiﬁcation of the uptake of the radiotracers [128,129].
2.3. Antioxidant therapies
Given the role of oxidative stress in PD pathogenesis, several
agents with antioxidant properties have been studied in clinical trials,
including selegiline, vitamin E, and rasagiline. Selegiline reduces
dopamine oxidation by inhibitingmonoamine oxidase B (MAO-B) and
is the antioxidant drug most studied in clinical trials. The DATATOP
trial was the largest clinical trial to investigate the neuroprotective
potential of selegiline, along with vitamin E, in patients with early PD
[141,142]. 800 patients were randomized to placebo, vitamin E,
selegiline, or the combination of vitamin E and selegiline, andevaluated every 3 months up to a maximum of 24 months. The
primary outcome was the time to clinical decision to treat with L-
dopa. Selegiline did signiﬁcantly delay the time of onset of L-dopa
treatment. Those treated with vitamin E showed no difference
compared to placebo-treated patients, and vitamin E did not appear
to add any beneﬁt to selegiline's effects. While this study suggests that
selegiline may delay disease progression, the unanticipated confoun-
der was that selegiline itself likely has mild symptomatic effects that
improve motor symptoms in PD.
Rasagiline is a newer MAO-B inhibitor that is more potent than
selegiline and hasmetabolites with potential antioxidant properties. It
has been studied using a delayed-start clinical trial design intended to
reduce the confounding effect of symptomatic efﬁcacy (Fig. 1). The
TEMPO study enrolled 404 patients with early PD who were treated
with placebo or rasagiline for 6 months and then all were placed on
rasagiline for another 6 months [143]. The primary outcome was
change in UPDRS score from baseline at 12 months. Those treated
initially with rasagiline had a smaller increase in UPDRS scores
compared to those ﬁrst started on placebo. Because all patients were
on rasagiline at the end of the study, it is assumed that symptomatic
effects of rasagiline were similar between the two groups. This study
does suggest that early treatment confers a long-lasting improvement,
but the overall duration of this study was relatively short, and the
group sizes were modest. A larger study (ADAGIO) to verify these
initial results in a larger sample and over a longer time course is
currently ongoing.
Coenzyme Q10 (CoQ10) is a cofactor in the electron transport
chain in mitochondria and has been shown to reduce dopaminergic
neurodegeneration in mouse PD models [144]. A small pilot study of
80 patients compared patients treated with CoQ10 at 300 mg, 600mg,
or 1200 mg to patients treated with placebo [145]. Patients were
followed for 16 months or until they required L-dopa treatment. The
primary outcome was change in total UPDRS compared to baseline.
There was a trend towards reduction in UPDRS score change in
patients treated with CoQ10 compared to placebo (p=0.09), and
secondary analysis suggested thatmost of the beneﬁt was in the group
treated with 1200 mg of CoQ10. More recently, CoQ10 has been
examined using a “futility study” [146]. This design employs small
group sizes and is intended to identify treatmentswhich clearly do not
have a signiﬁcant effect on disease progression and, therefore, should
be excluded from further study [147–149]. In this paradigm, CoQ10 did
not meet the criteria for futility, and a larger, long-term study
comparing high doses of CoQ10 to placebo has recently been initiated.
Creatine promotes mitochondrial ATP production and has been
shown to be neuroprotective in animal models [150]. A pilot study
compared 60 patients with early PD treated with either creatine or
placebo for two years [151]. No difference was seen in UPDRS score or
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of the individual UPDRS subscales showed a difference in the
“mentation, behavior, and mood” section. Creatine has also been
examined in the futility study paradigm and could not be rejected as
futile [86]. A large phase III trial examining creatine's effect on disease
progression in a diverse population of patients with different stages of
PD is in progress.
While none of these clinical studies have convincingly shown that
these antioxidant therapies slow disease progression, several of these
trials indicate that selegiline, rasagiline, and CoQ10 may be
promising. In addition, all of the antioxidant approaches have a
good safety record, a desirable property in a neuroprotective therapy
that may need to be administered to a large number of patients for
many years.
2.4. Anti-apoptotic agents
Several anti-apoptotic agents have been examined in controlled
clinical trials. The propargylamine TCH346 is an anti-apoptotic factor
that inhibits the glycolytic enzyme glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), which can initiate apoptosis. Although
TCH346 was shown in both 6-OHDA and MPTP animal models to
reduce dopaminergic cell loss [152,153], a double-blind, randomized
trial involving 301 patients over 12 to 18 months failed to show a
signiﬁcant difference in clinical outcome [107]. CEP-1347, an inhibitor
of mixed lineage kinases that can activate the c-Jun N-terminal kinase
(JNK) pathway involved in cell death, is another anti-apoptotic agent
that showed promise in preclinical studies [154–156]. The PRECEPT
trial involved 806 patients with early PD randomized to placebo or
CEP-1347, and the primary outcome was time to need for dopami-
nergic therapy [108]. This studywas terminated early when an interim
analysis revealed futility of the experimental treatment.
The failure of these two anti-apoptotic drugs has raised a number
of important questions. Both were very effective in commonly used
neurotoxin-based animal models of PD, raising the question of the
predictive validity of these models. These failures have also raised the
questions of whether anti-apoptotic strategies are an effective
approach when applied at the relatively late stage of the disease
when symptoms are clinically evident and whether anti-apoptotic
therapies would need to be combined with trophic support [157].
2.5. Trophic factors
Several neurotrophic factors have been examined in human
clinical trials. Glial-derived neurotrophic factor (GDNF) is a potent
neurotrophic factor that supports the survival of dopaminergic nigral
neurons and has been shown to be neuroprotective in animal models
for PD [112,113,158]. So far, it has been delivered primarily by direct
infusion of the protein into the brain. A small, open-label trial
suggested effectiveness [117], but a larger controlled study involving
34 PD patients was halted because of lack of efﬁcacy [118]. In
addition, serious, device-related adverse events occurred in three
patients, and several patients developed serum antibodies to GDNF.
After the onset of the human trial, a toxicology study revealed that
some monkeys infused with high doses of GDNF showed cerebellar
cell loss, raising further concerns regarding the safety of GDNF
infusions [118].
An alternative to direct infusion of trophic factors is delivery of
these agents by gene transfer approaches [159]. Recent gene therapy
efforts have used neurturin, a neurotrophic factor related to GDNF that
also promotes dopaminergic neuronal survival in culture [160,161].
Delivery of an adeno-associated viral (AAV-2) vector containing
neurturin (CERE-120) protected against dopaminergic cell loss and
improved motor function in MPTP-treated monkeys [116] and in 6-
OHDA-treated rats [114,115]. CERE-120 has been tested for its safety in
an open-label clinical study involving 12 patients with advanced PD[162]. The treatment was well tolerated, and there was evidence for a
substantial clinical effect: off-medication UPDRS motor subscore was
signiﬁcantly reduced and mean on time was increased at one year
following injection. While these ﬁndings are promising, data from
open-label trials must be interpreted cautiously. A larger double-blind
study is in progress.
Neuroimmunophilins, intracellular receptor proteins that bind
immunosuppressive drugs like cyclosporine and FK506, are highly
expressed in the brain and can promote neuronal growth indepen-
dently of their immunosuppressive effects [163–165]. Neuroimmu-
nophilin ligands have shown some evidence of neuroprotection in 6-
OHDA and MPTP animal models [166–168], although neurodegenera-
tion has not been reduced in all PD animal models [169,170]. The
mechanism of action is unknown but may involve the induction of
neurotrophic factors [171] or the antioxidant glutathione [172,173]. A
recent phase II trial of the neuroimmunophilin ligand GPI-1485
showed no signiﬁcant difference of motor symptoms in patients with
mild to moderate PD treated with GPI-1485 for 6 months compared to
those treatedwith placebo [174]. However, therewas a non-signiﬁcant
trend of increased β-CIT uptake in those patients taking the highest
dose of GPI-1485 [174].
3. Lessons from clinical trials of neuroprotective therapy
Despite the promise of several different neuroprotective strategies,
none of the human clinical trials completed so far have shown any
therapy to have clear disease-modifying effects. These human studies
have not focused only on a single pathogenic mechanism, but a wide
range of potential pathogenic mechanisms have been explored. Some
of the agents studied do appear to have potential neuroprotective
effects, and our current trial designs may be preventing us from
adequately detecting neuroprotection in humans. What are some of
the limitations of testing for neuroprotection that may have lead to
these “failures”?
3.1. Limitation of clinical measures of disease
One major issue in determining whether a therapy is neuropro-
tective in human PD is how to test neuroprotection in a living patient.
Traditionally, clinical measures based on neurological exam have been
used to assess progression (or lack of progression) of PD. The UPDRS
scale involves clinical examination of motor function combined with
scales rating patient's subjective view of function in daily activities.
There are several limitations to this scale [175,176]. First, available
symptomatic treatments have a large effect on the UPDRS scale, which
may obscure evidence of neuroprotection. The scale is also heavily
weighted towards motor dysfunction, particularly tremor-related
symptoms. Much of the disability associated with PD is not considered
in the scale, such as that related to autonomic dysfunction. A new
version of the UPDRS is currently under development, which may
address some of these limitations [177].
To overcome the potentially confounding symptomatic effects of a
treatment, many trials have incorporated a washout period before
assessing the primary outcomemeasure. However, these symptomatic
drug effects may be longstanding and outlast the washout period
[178]. An alternative approach has been to use a delayed-start design
where one group of patients is started on the therapy several months
before the comparative group (Fig. 1) [178]. This approach is based on
the assumption that the symptomatic effects would be similar across
the groups at the end of the study. However, there are still some
potential problems with this approach [143]. For example, longer
treatment may result in increased sensitivity to drug. The delayed-
start paradigm may also result in different rates of drop out between
groups, as patients randomized to placebo start aremore likely to drop
out. Many investigators regard the delayed-start design as the best
available approach for evaluating neuroprotection.
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In laboratory studies the “gold standard” for evaluating neuropro-
tection is direct counts of surviving dopamine neurons, an approach
not currently feasible in living patients. SPECT and PET imaging have
been used as surrogate measures of dopamine cell numbers, yet these
imaging techniques, which are based on dopamine neurochemistry,
have their limitations [128,129]. β-CIT SPECT imaging measures the
binding of the radioactive tracer to the dopamine transporter on
dopaminergic terminals in the striatum, while [18F]ﬂuorodopa PET
imaging measures the conversion of the radioactive tracer into
ﬂuorodopamine within the terminals. Although they rely on different
aspects of dopamine neurochemistry, a concernwith both approaches
is that the underlying chemistry may be altered by the pharmacolo-
gical effects of the treatments under investigation such that imaging
changes may not necessarily reﬂect changes in dopaminergic neuron
counts [128]. None of these imaging techniques have yet been
validated as appropriate surrogate measures of neuroprotection
through correlation with neuropathology and/or clinical symptoms
[129,179,180], and considerably more long-term data with these
methods is required.
3.3. Limitations of animal models
The failure of so many potential neuroprotective therapies could
also be explained by the limitations of animal models. Currently, there
is no one animal model for PD that mimics the full pathology and
clinical symptomology of the illness. Traditionally, preclinical studies
have focused on toxin-based models using 6-OHDA or MPTP. Both of
these models show degeneration of SN neurons, but the time course
and pathological features of these models are different from human
disease [122,181]. Perhaps more importantly, there is no substantial
evidence for a role of either of these toxins in human PD. With the
discovery of α-syn, parkin, and other proteins identiﬁed through
genetic PD studies, genetic-based models have been developed as
alternatives to toxin-based models. These models incorporate some
additional features of the disease, but still fall short of an authentic re-
creation. For example, transgenic mice that either express mutant α-
syn (A30P or A53T) or overexpress wildtype α-syn show variable
motor deﬁcits, α-syn inclusions, and dopamine terminal loss, but
none of these transgenic animals show actual loss of dopaminergic
neurons [182,183].
The predictive power of animal models of PD will be conﬁrmed
only if there is some success in demonstrating neuroprotection in
humans. In the meantime, most in the ﬁeld rely on examining
effectiveness of potential treatments in several different animal
models, with the hope that treatments exhibiting a broad effect in
these diverse models are the ones mostly likely to exhibit effective-
ness against human disease.
3.4. Heterogeneity and time course of the disease
The discovery of genes that cause PD has emphasized the diversity of
the disorder: not only does it involve anatomical sites outside the
dopaminergic system, but it likely also has a variety of interrelated
causes. Most of the single-genemutations discovered so far are rare and
unlikely to play a signiﬁcant role in broad-based clinical trials; however,
parkin mutations are relatively frequent in young-onset patients
[48,184,185], and LRRK2 mutations may account for 2% of a general
clinical population of PD [186–189]. A more problematic issue is that
there are likely a number of genetic risk factors for PD, which could alter
the response to putative neuroprotective strategies. Therefore, deﬁning
subgroups of PD may be essential in order to establish neuroprotective
efﬁcacy. In addition, as PD involves many different pathogenic mechan-
isms, several agents may need to be combined to block multiple
pathways in order to achieve neuroprotection.For a potential neuroprotective agent to be most effective, patients
need to be treated early, before much cell loss has occurred. By the
time most patients develop the typical clinical symptoms of PD, it is
estimated that at least 60% of nigral dopamine neurons have
degenerated [190–192]. They may already have a variety of non-
motor symptoms, including sleep disturbance and autonomic dys-
function [193]. Such earlier symptoms are guiding the ongoing search
for methods to detect “pre-symptomatic” PD, ranging from simple
tests of olfaction to sophisticated neuroimaging studies.
4. The future of neuroprotection
In 2003, the NIH-appointed Committee to Identify Neuroprotective
Agents in Parkinson's (CINAPS) published an assessment of potential
neuroprotective compounds and prioritized 12 compounds to be
studied further in clinical trials [194]. Since then, the list of potential
therapies has grown longer, but a convincing success in human trials is
still awaited. Of those strategies still under active study, several of the
most promising are listed below. A common theme among several of
these strategies is that interest is driven largely by the results of
human genetic, pathological, and epidemiological studies — perhaps
reﬂecting a concern in the ﬁeld that an animal model with useful
predictive properties in terms of neuroprotection has not yet been
identiﬁed. The wealth of information regarding PD pathogenesis from
genetic studies is leading to novel approaches to neuroprotection
based on the biology of α-syn, LRRK2, and others. While much more
research is needed before translating such theoretical therapies into
clinical trials, these approaches may lead to therapies that protect not
only against dopaminergic cell loss but also against the loss of other
neuronal populations at risk in PD and related disorders.
4.1. Adenosine receptor antagonists
Epidemiological studies have indicated that caffeine may reduce
the incidence of PD, at least in men [195,196]. As caffeine mediates its
action by antagonizing adenosine receptors, this ﬁnding has led to
interest in evaluating adenosine receptor antagonists as potential
neuroprotective agents (reviewed in [197]). In the striatum, the A2a
receptor can heterodimerize with the D2 receptor to inhibit dopamine
signaling [198,199], while inhibition of the A2a receptor can promote
dopamine function. Two small clinical trials of the A2a antagonist
istradefylline (KW-6002) has demonstrated potential symptomatic
effects in advanced PD [200,201]. More recent research has suggested
that A2a antagonists not only improve symptomatic function in PD but
may also be neuroprotective. Caffeine and istradefylline are both
neuroprotective in the MPTP model [202,203], and caffeine (and
related A2a antagonists) has been identiﬁed by CINAPS as a priority
agent to be evaluated for neuroprotection in clinical trials [194]. A
potential advantage of A2a antagonists is that they have also been
shown to be neuroprotective in non-dopaminergic brain areas in
animal models [204–206] so that they may protect against PD
neurodegeneration found in regions besides the SN.
4.2. Anti-inﬂammatory agents
The role of inﬂammation in PD has become more recognized
recently. Activation of microglia, increased cytokine production, and
increased complement protein levels have been demonstrated in PD
(reviewed in [63–65]). As a means to slow disease progression, anti-
inﬂammatory agents, including NSAIDs and minocycline, have been
pursued as potential disease-modifying treatments for PD. Several
studies in culture and in animal models have shown that certain
NSAIDs, such as aspirin, have neuroprotective qualities, although there
is conﬂicting data regarding which NSAIDs, what dosing, and what
timing provides the best neuroprotection (reviewed in [64]).
Epidemiological studies examining the association of regular NSAID
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study by Chen et al. showed that NSAID use lowers the risk of PD by
45% [81], and a followup study by the same group showed that only
ibuprofen had this neuroprotective effect [80]. Other epidemiological
studies examining this association have shown nonsigniﬁcant trends
or have shown this association only in men [79,82,83]. At this time, it
is unclear that any of the currently available NSAIDs have genuine
neuroprotective properties in PD, but the more general strategy of
targeting the mechanisms of neuroinﬂammation seems very
promising.
An example of an alternative approach to targeting neuroinﬂam-
mation may be the use of statins (3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitors). In addition to lowering cholesterol,
these drugs have anti-inﬂammatory effects, including reduction of
TNFα, nitric oxide, and superoxide production by microglia [207].
Statins may also act to scavenge free radicals [208]. Simvastatin has
been shown to reduce dopamine loss in MPTP animal models [207].
Recent epidemiological studies showed that statin use, particularly
simvastatin, is associated with reduced PD incidence [84,85]. A
limitation of these studies is that the use of statins was not
randomized. Other studies have suggested low LDL cholesterol levels
increased PD risk [209,210], so that the increased use of statins among
controls may just reﬂect high LDL levels that would be protective
against PD. These issues need to be explored in a prospective,
randomized study.
Minocycline, a second generation tetracycline long used as an
antimicrobial agent, has anti-inﬂammatory effects independent of its
antimicrobial activity. Minocycline blocks microglial activation and
may also have anti-apoptotic activity in culture [211,212]. It protects
against dopaminergic cell loss in both the MPTP and 6-OHDA animal
models [213–215]. A recent futility study showed that minocycline
was well tolerated and could not be rejected as futile, setting the stage
for larger phase III trials [86].
4.3. Other antioxidants
Epidemiological studies have pointed to uric acid as a potential
neuroprotective agent in PD. Uric acid acts as an antioxidant by
scavenging reactive oxygen and nitrogen species [216]. Studies have
shown a decreased incidence of PD among subjects with high serum
urate levels [217–219] and among subjects with gout [220]. In patients
with early PD, higher plasma urate levels correlatewith slower disease
progression [221]. Uric acid can reduce dopaminergic cell death in
response to rotenone and homocysteine in culture [222]. A recent
study showed that subjects on diets that promote high urate levels
have a reduced risk of developing PD [223]. Such a urate-rich diet
could serve as a neuroprotective therapy in PD. However, the potential
beneﬁts of a urate-rich diet have to be weighed against the risk of
developing gout and cardiovascular disease. A large-scale clinical trial
of the effectiveness of elevating urate in patients with PD is in the
planning stages.
4.4. Alpha-synuclein-directed therapies
Although its mechanism for inducing neurotoxicity is not well
understood, α-syn appears to be an important mediator of toxicity in
PD. Disruption of α-syn aggregation has been the focus of research to
develop novel therapies against PD. Alpha-synuclein aggregation can
be reduced at several levels: 1) by reducingα-syn protein production;
2) by increasing α-syn clearance; 3) by preventing or reducing
chemical modiﬁcations that can promote aggregated species; or 4) by
directly interfering with aggregation. Potential methods to reduce α-
syn protein production include small-molecule modiﬁers of transcrip-
tion and RNAi-basedmethods to knock down translation. Increasedα-
syn clearance could become enhanced by activation of proteosomal or
lysosomal pathways. Augmentation of parkin or UCH-L1 activity couldpromote the clearance of α-syn and other aggregated proteins.
Indeed, parkin overexpression can rescue cells from α-syn pathology
in animal models [224–226]. Promotion of chaperone function could
also promote α-syn clearance. The chaperone protein Hsp70 can
reduce insoluble α-syn aggregates in vitro and in vivo [58], and the
compound geldanamycin can reduce α-syn aggregation in vitro by
increasing Hsp70 levels [227]. Activation of lysosomal degradation
could also induce α-syn clearance; the lysosomal enzyme cathepsin D
reduces α-syn aggregation and toxicity in culture and in animal
models [228]. In addition, vaccine-based therapies have been pursued
as potential strategies for increasingα-syn clearance. Alpha-synuclein
transgenic mice vaccinated against α-syn showed decreased α-syn
accumulation secondary to increased degradation via lysosomal
pathways [229]. As oxidative modiﬁcation and phosphorylation of
α-syn both promote aggregation of α-syn [35,230,231], antioxidant
therapies and kinase inhibitors could also help reduce α-syn
aggregation and toxicity.
Finally, direct blockers of α-syn aggregation could be developed
into therapeutic strategies for PD. Peptide-based inhibitors have been
developed that can block α-syn self-association and aggregation
[232–234]. The chaperone-like proteins, β-syn and 14-3-3 proteins,
have also been demonstrated to reduce α-syn aggregation [235–237],
and increasing their expression and/or function could serve as a basis
for therapeutic intervention. All of these strategies are at a relatively
early stage of development and await further study before proceeding
to human intervention trials.
4.5. Kinase inhibitors
The most common genetic cause of PD to date is mutation in the
gene LRRK2, which causes about 2% of all cases of PD [186–189] and up
to 40% in historically isolated populations [238–241]. The LRRK2 gene
codes for a large protein, also known as dardarin, which contains a
serine/threonine kinase domain and a GTPase domain. The native
function of this protein is currently poorly understood. The most
common pathogenic mutation of LRRK2 is associated with increased
kinase activity [242–244]. Evidence that pathogenic mutations
increase this activity makes the kinase activity of LRRK2 an important
target for neuroprotective therapy. Kinases are generally good targets
for small molecule therapies, and indeed certain therapies in other
diseases are based on inhibition of kinase activity. At this time,
however, the endogenous substrates for LRRK2 are unknown, making
it difﬁcult to devise the development of LRRK2 kinase inhibitors. As
the function of LRRK2 is further characterized, a clearer therapeutic
strategy based on LRRK2 biology should become more apparent.
4.6. Trophic factors
Trophic factor approaches are one of the older strategies for
neuroprotective therapy in PD, but also an approach with substantial
promise for the future (see above). A strength of this approach is that
the biology of the factors themselves is well known, and it does not
rely on a detailed understanding of the mechanisms of cell death in
PD. Trophic factors may enhance dopaminergic survival, regardless of
the mechanism of cell death. On the other hand, at least as presently
conceived, they directly target the dopaminergic deﬁcit and not the
non-dopaminergic aspects of the disease. The studies of gene therapy
delivery of neurturin are in an advanced stage, and if successful will
not only provide an immediate treatment for many patients with PD,
but may also open to the door to a wider range of gene therapy
approaches.
5. Conclusions
Neuroprotection in PD remains an important but elusive goal. A
successful neuroprotective treatment could transform PD from a
683T.A. Yacoubian, D.G. Standaert / Biochimica et Biophysica Acta 1792 (2009) 676–687relentlessly progressive and disabling disease to a problem that can be
managed with only a modest effect on quality of life. Current barriers
include a lack of knowledge of the basic mechanisms of PD, and
deﬁciencies in the methodology used to study disease progression.
Overall, however, the activity aimed at understanding and treating PD
has grown exponentially and should ultimately result in better
therapies for PD.
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